Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 103614315 | 10361431 | 5 | F | 201204 | 20160816 | 20140805 | 20160822 | EXP | CA-ROCHE-1444831 | ROCHE | 50.99 | YR | F | Y | 0.00000 | 20160822 | CN | CA | CA |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 103614315 | 10361431 | 1 | PS | XOLAIR | OMALIZUMAB | 1 | Subcutaneous | 300 MG, BIW | U | S0002F | 103976 | 300 | MG | SOLUTION FOR INJECTION | QOW | ||||
| 103614315 | 10361431 | 2 | SS | XOLAIR | OMALIZUMAB | 1 | Subcutaneous | 300 MG, BIW | U | S0002F | 103976 | 300 | MG | SOLUTION FOR INJECTION | QOW | ||||
| 103614315 | 10361431 | 3 | SS | XOLAIR | OMALIZUMAB | 1 | Subcutaneous | 300 MG, BIW | U | S0002F | 103976 | 300 | MG | SOLUTION FOR INJECTION | QOW | ||||
| 103614315 | 10361431 | 4 | SS | XOLAIR | OMALIZUMAB | 1 | Subcutaneous | UNK | U | S0002F | 103976 | SOLUTION FOR INJECTION | |||||||
| 103614315 | 10361431 | 5 | SS | XOLAIR | OMALIZUMAB | 1 | Subcutaneous | UNK | U | S0002F | 103976 | SOLUTION FOR INJECTION | |||||||
| 103614315 | 10361431 | 6 | SS | XOLAIR | OMALIZUMAB | 1 | Subcutaneous | UNK | U | S0002F | 103976 | 300 | MG | SOLUTION FOR INJECTION | QOW | ||||
| 103614315 | 10361431 | 7 | SS | XOLAIR | OMALIZUMAB | 1 | Subcutaneous | UNK | U | S0002F | 103976 | SOLUTION FOR INJECTION | |||||||
| 103614315 | 10361431 | 8 | C | FLU VACCINE | INFLUENZA VIRUS VACCINE | 1 | Unknown | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 103614315 | 10361431 | 1 | Asthma |
| 103614315 | 10361431 | 8 | Prophylaxis |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 103614315 | 10361431 | OT |
| 103614315 | 10361431 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 103614315 | 10361431 | Appendicitis perforated | |
| 103614315 | 10361431 | Asthma | |
| 103614315 | 10361431 | Basal cell carcinoma | |
| 103614315 | 10361431 | Blood pressure increased | |
| 103614315 | 10361431 | Body temperature decreased | |
| 103614315 | 10361431 | Cough | |
| 103614315 | 10361431 | Hypersensitivity | |
| 103614315 | 10361431 | Joint injury | |
| 103614315 | 10361431 | Lower limb fracture | |
| 103614315 | 10361431 | Pain | |
| 103614315 | 10361431 | Peripheral swelling |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 103614315 | 10361431 | 1 | 20050427 | 0 | ||
| 103614315 | 10361431 | 2 | 20110623 | 0 | ||
| 103614315 | 10361431 | 3 | 20130516 | 0 | ||
| 103614315 | 10361431 | 4 | 20131223 | 0 | ||
| 103614315 | 10361431 | 5 | 20140107 | 0 | ||
| 103614315 | 10361431 | 6 | 20050516 | 0 | ||
| 103614315 | 10361431 | 7 | 20160705 | 0 | ||
| 103614315 | 10361431 | 8 | 20121017 | 0 |